Randomized phase II designs
L Rubinstein, J Crowley, P Ivy, M LeBlanc… - Clinical Cancer …, 2009 - AACR
As the use of molecularly targeted agents, which are anticipated to increase overall survival
(OS) and progression-free survival (PFS) but not necessarily tumor response, has increased …
(OS) and progression-free survival (PFS) but not necessarily tumor response, has increased …
Randomized phase II designs
L Rubinstein, J Crowley, P Ivy… - Clinical Cancer …, 2009 - mayoclinic.elsevierpure.com
As the use of molecularly targeted agents, which are anticipated to increase overall survival
(OS) and progression-free survival (PFS) but not necessarily tumor response, has increased …
(OS) and progression-free survival (PFS) but not necessarily tumor response, has increased …
Randomized phase II designs
L Rubinstein, J Crowley, P Ivy… - … : an official journal …, 2009 - pubmed.ncbi.nlm.nih.gov
As the use of molecularly targeted agents, which are anticipated to increase overall survival
(OS) and progression-free survival (PFS) but not necessarily tumor response, has increased …
(OS) and progression-free survival (PFS) but not necessarily tumor response, has increased …
[HTML][HTML] Randomized Phase II Designs
L Rubinstein, J Crowley, P Ivy, M LeBlanc… - … cancer research: an …, 2009 - ncbi.nlm.nih.gov
As the use of molecularly targeted agents, which are anticipated to increase overall and
progression-free survival (OS and PFS), but not necessarily tumor response, has increased …
progression-free survival (OS and PFS), but not necessarily tumor response, has increased …
[引用][C] Randomized Phase II Designs: Phase II Trials: Designs for the future
L RUBINSTEIN, J CROUULEY, P LVY… - Clinical cancer …, 2009 - pascal-francis.inist.fr
Randomized Phase II Designs : Phase II Trials: Designs for the future CNRS Inist Pascal-Francis
CNRS Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
CNRS Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …
Randomized phase II designs.
L Rubinstein, J Crowley, P Ivy, M Leblanc… - … cancer research: an …, 2009 - authors.fhcrc.org
As the use of molecularly targeted agents, which are anticipated to increase overall survival
(OS) and progression-free survival (PFS) but not necessarily tumor response, has increased …
(OS) and progression-free survival (PFS) but not necessarily tumor response, has increased …
[PDF][PDF] Randomized Phase II Designs
L Rubinstein, J Crowley, P Ivy, M LeBlanc, D Sargent - core.ac.uk
As the use of molecularly targeted agents, which are anticipated to increase overall and
progression-free survival (OS and PFS), but not necessarily tumor response, has increased …
progression-free survival (OS and PFS), but not necessarily tumor response, has increased …
Randomized phase II designs.
L Rubinstein, J Crowley, P Ivy, M Leblanc… - … Cancer Research: an …, 2009 - europepmc.org
As the use of molecularly targeted agents, which are anticipated to increase overall and
progression-free survival (OS and PFS), but not necessarily tumor response, has increased …
progression-free survival (OS and PFS), but not necessarily tumor response, has increased …
Randomized Phase II Designs
L Rubinstein, J Crowley, P Ivy, M LeBlanc… - Clinical Cancer …, 2009 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> As the use of molecularly targeted agents,
which are anticipated to increase overall survival (OS) and progression-free survival (PFS) …
which are anticipated to increase overall survival (OS) and progression-free survival (PFS) …
[PDF][PDF] Randomized Phase II Designs
L Rubinstein, J Crowley, P Ivy, M LeBlanc, D Sargent - Citeseer
As the use of molecularly targeted agents, which are anticipated to increase overall and
progression-free survival (OS and PFS), but not necessarily tumor response, has increased …
progression-free survival (OS and PFS), but not necessarily tumor response, has increased …